Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von Persönlichkeits- und Verhaltensstörungen

  • Chapter
Kompendium der Psychiatrischen Pharmakotherapie

  • 5061 Accesses

Zusammenfassung

Definition, Abgrenzung und Klassifikation dieser Störungen sind nicht abgeschlossen; auch der Begriff Persönlichkeitsstörung ist umstritten. Nach ICD-10 und DSM-IV/DSM-5 werden Persönlichkeitsstörungen generell als meist früh in Kindheit oder Jugend beginnende, anhaltende Muster von rigiden, nichtangepassten Denk- und Verhaltensweisen, die sich in nahezu allen Lebensbereichen (eigenes Erleben, Beziehungen, Beruf) als Störung für den Betreffenden oder die Umwelt äußern, konzeptualisiert. Die vorherrschenden, prägnanten Symptome, die oft kombiniert auftreten, werden nach ICD-10 und DSM-5 Subtypen und Cluster (DSM) von Persönlichkeitsstörungen (oder Diagnosen) zugeordnet, eine Diagnose ist prinzipiell ab dem späteren Jugendalter möglich.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Amad A, Thomas P, Perez-Rodriguez MM (2015) Borderline personality disorder and oxytocin: review of clinical trials and future directions. Curr Pharm Des 21: 3311–3316

    Google Scholar 

  • Bevilacqua L, Carli V, Sarchiapone M et al (2012) Interaction between FKBP5 and childhood trauma and risk of aggressive behavior. Arch Gen Psychiatry 69: 62–70

    Google Scholar 

  • Bellino S, Bozzatello P, Rocca G et al (2014) Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 28: 125–132

    Google Scholar 

  • Black DW, Zanarini MC, Romine A et al (2014) Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 171: 1174–1182

    Google Scholar 

  • Bolm T (2015) Therapie der Borderline-Persönlichkeitsstörung. DNP – Der Neurologe & Psychiater 16: 34–37

    Google Scholar 

  • Borschmann R, Henderson C, Hogg J et al (2012) Crisis interventions for people with borderline personality disorder. Cochrane Database Syst Rev: CD009353

    Google Scholar 

  • Bridler R, Häberle A, Müller ST et al (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25: 763–772

    Google Scholar 

  • Brüne M (2015) On the role of oxytocin in borderline personality disorder. Br J Clin Psychol [Epub ahead of print]

    Google Scholar 

  • Falkai P, Wittchen HU (Hrsg) (2015) DSM-5. Diagnostisches und Statistisches Manual Psychischer Störungen. Hogrefe, Göttingen

    Google Scholar 

  • Gunderson JG, Stout RL, McGlashan TH et al (2011) Ten-year course of borderline personality disorder. Arch Gen Psychiatry 68: 827–837

    Google Scholar 

  • Herpertz SC, Bertsch K (2015) A new perspective on the pathophysiology of borderline personality disorder: a model of the role of oxytocin. Am J Psychiatry 172: 840–851

    Google Scholar 

  • Ingenhoven TJ, Duivenvoorden HJ (2011) Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol 31(4): 489–496

    Google Scholar 

  • Ingenhoven T, Lafay P, Rinne T et al (2010) Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 71: 14–25

    Google Scholar 

  • Rosenbluth M, Sinyor M (2012) Off-label use of atypical antipsychotics in personality disorders. Expert Opin Pharmacother 13: 1575–1585

    Google Scholar 

  • Salvatore JE, Edwards AC, McClintick JN et al (2015) Genome-wide association data suggest ABCB1 and immune-related gene sets may be involved in adult antisocial behavior. Transl Psychiatry 5: e558

    Google Scholar 

  • Schwerthöffer D, Bäuml J, Rentrop M (2013) Pharmakotherapie der Borderline-Störung: Praxis und Studienlage. Fortschr Neurol Psychiatr 81: 437–443

    Google Scholar 

  • Stoffers J, Völlm BA, Rücker G et al (2010) Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 6: CD005653

    Google Scholar 

  • Stoffers JM, Völlm BA, Rücker G et al (2012) Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev: CD005652

    Google Scholar 

  • Stoffers-Winterling J, Lieb K (2015) Pharmakotherapie von Borderline-Persönlichkeitsstörungen – Versorgungsalltag versus aktuelle externe Evidenz. Info Neurol Psychiatrie 17: 51–55

    Google Scholar 

  • Strüber N, Strüber D, Roth G (2014) Impact of early adversity on glucocorticoid regulation and later mental disorders. Neurosci Biobehav Rev 38:17–37

    Google Scholar 

  • Werner KB, Few LR, Bucholz KK (2015) Epidemiology, comorbidity, and behavioral genetics of antisocial personality disorder and psychopathy. Psychiatr Ann 45: 195–199

    Google Scholar 

  • Welander-Vatn A, Ystrom E, Tambs K et al (2016) The relationship between anxiety disorders and dimensional representations of DSM-IV personality disorders: a co-twin control study. J Affect Disord 190: 349–356

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Marburg/Gießen

    Prof. Dr. med. Dr. rer. nat. Dipl.-Psych. M. J. Müller

  2. Mainz

    Prof. Dr. med. O. Benkert

Authors
  1. Prof. Dr. med. Dr. rer. nat. Dipl.-Psych. M. J. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. O. Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mainz

    Otto Benkert

  2. München

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Müller, M., Benkert, O. (2017). Medikamente zur Behandlung von Persönlichkeits- und Verhaltensstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50333-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50333-1_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50332-4

  • Online ISBN: 978-3-662-50333-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation